Sequencing Bispecifics and BCMA-Targeted Therapies in R/R MM
Panelists discuss how bispecifics are sequenced with other B-cell maturation antigen (BCMA)–targeted therapies, such as chimeric antigen receptor (CAR) T cells or antibody drug conjugates (ADCs), and whether early vs late relapse impacts treatment strategies for relapsed/refractory multiple myeloma (R/R MM), with emphasis on how biological and clinical factors influence decision-making.
Video content above is prompted by the following:
- How do you approach sequencing bispecifics with other BCMA-targeted therapies, such as CAR T cells or ADCs?
- Does the time frame of relapse—early vs late—alter your treatment sequencing strategies for R/R MM patients?
- How do the biological and clinical characteristics of early vs late relapse influence your decision-making process?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
